pp-152 Concentrate for solution for infusion
Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Metastatic castration-resistant prostate cancer (mCRPC) — post-AR pathway inhibitor
Clinical stage: Phase 2/3
Modality: Biologic (tumour-activated T-cell engager bispecific; PSMA×CD3; TRACTr platform)
Mechanism / Target: PSMA-targeting bispecific — activates CD3+ T cells at PSMA+ tumour site; pro-drug design: requires tumour-localised protease cleavage for T-cell engagement, limiting systemic cytokine release
Route / form: Intravenous infusion
Differentiation: Tumour-activated design reduces cytokine release syndrome vs classical T-cell engagers; PSMA-selective; incorporates IL-2 signalling for enhanced T-cell proliferation at tumour site
Manufacturer #39181
Clinical-stage immuno-oncology company developing tumour-activated T-cell engager therapies. Proprietary TRACTr platform enables conditional activation of bispecifics in the tumour microenvironment. Wholly owned pipeline targeting solid tumours with reduced systemic toxicity profile.
None